Calciscon AG

**Calciscon** is a Switzerland-based health care startup founded in 2013, specializing in the development and marketing of diagnostic devices for the assessment of calcification-related cardiovascular (CV) disease. The company's slogan, "**Calcification Propensity Diagnostics can predict effective drugs to slow down vascular calcification and prevent cardiovascular disease**," reflects its core mission. The flagship product of Calciscon is the T50 test, a unique measurement of calcification that provides critical medical information to enable individualized care and reduce calcification to prevent cardiovascular disease. This test addresses a multi-billion market opportunity, with an initial focus on patients with advanced chronic kidney disease (CKD), a high-risk group for calcification-related CV events. Attracting a notable Fr.2.50M Series A investment from **Yellowstone Holding** on April 14, 2021, Calciscon is well-poised for growth and innovation in the health care industry. By enabling doctors to identify high-risk patients and select the most effective therapy to reduce calcification and improve patient CV prognosis, Calciscon is making significant strides in addressing a critical aspect of CV disease, the leading cause of death globally. Investors and industry observers should keep a close eye on Calciscon as it continues to make advancements in the field of cardiovascular diagnostics, potentially revolutionizing the approach to preventing and treating calcification-related CV disease.